Session » Systemic Sclerosis & Related Disorders – Clinical II: Lessons Learned from Clinical Trials & Cohorts (2038–2042)
- 4:00PM-4:50PM
-
Abstract Number: 2042
A Low FODMAP Diet Is Not Associated with Decreased GI Symptoms or Changes in GI Microbial Composition in Patients with Systemic Sclerosis
- 4:00PM-4:50PM
-
Abstract Number: 2038
Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis
- 4:00PM-4:50PM
-
Abstract Number: 2040
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON
- 4:00PM-4:50PM
-
Abstract Number: 2041
Disease Features of Systemic Sclerosis Are Associated with Alterations in Gastrointestinal Microbial Composition in Two Independent Cohorts
- 4:00PM-4:50PM
-
Abstract Number: 2039
Short Telomeres and Autoantibodies Targeting Telomere-Associated Proteins in Scleroderma